ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock par value $0.012 per share
Symbol
ORMP on Nasdaq
Shares outstanding
41,009,592
Price per share
$3.07
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
9,209,933
Total reported value
$24,309,179
% of total 13F portfolios
0%
Share change
-14,346
Value change
+$25,895
Number of holders
47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
KIDRON NADAV 7.6% $6,856,804 3,116,729 Nadav Kidron 11 Feb 2025
BML Investment Partners, L.P. 6.6% $5,605,083 2,643,907 BML Investment Partners, L.P. 31 Dec 2024

As of 30 Sep 2025, 47 institutional investors reported holding 9,209,933 shares of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP). This represents 22% of the company’s total 41,009,592 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) together control 22% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BML Capital Management, LLC 7.7% 3,167,231 +2.7% 7.7% $8,361,490
Aquamarine Financial (Cayman) Ltd 4.8% 1,973,057 0% 0.53% $5,208,870
Murchinson Ltd. 4.3% 1,751,559 0% 0.89% $4,624,116
BOOTHBAY FUND MANAGEMENT, LLC 2.1% 845,391 0% 0.06% $2,231,832
Rathbones Group PLC 0.57% 233,018 0% 0% $615,167
BANK OF AMERICA CORP /DE/ 0.36% 149,667 +4.4% 0% $395,121
RENAISSANCE TECHNOLOGIES LLC 0.36% 148,900 +3.3% 0% $393,096
DIMENSIONAL FUND ADVISORS LP 0.36% 147,487 -12% 0% $389,365
WELLS FARGO & COMPANY/MN 0.32% 130,086 +520% 0% $343,426
CITADEL ADVISORS LLC 0.27% 111,707 +28% 0% $294,906
BlackRock, Inc. 0.27% 109,733 +28% 0% $289,696
JANE STREET GROUP, LLC 0.15% 59,659 +41% 0% $157,500
RBF Capital, LLC 0.1% 42,947 0% 0.01% $113,380
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.09% 36,825 -24% 0% $97,218
Squarepoint Ops LLC 0.07% 29,866 -35% 0% $78,846
Connor, Clark & Lunn Investment Management Ltd. 0.07% 28,243 -53% 0% $74,562
GEODE CAPITAL MANAGEMENT, LLC 0.06% 24,282 0% 0% $64,104
XTX Topco Ltd 0.06% 23,885 0% $63,056
PNC Financial Services Group, Inc. 0.06% 23,200 0% 0% $61,248
AMERICAN CENTURY COMPANIES INC 0.05% 19,591 0% 0% $51,720
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC 0.05% 18,799 0% 0% $46,622
MORGAN STANLEY 0.04% 16,924 -47% 0% $44,680
Sage Capital Management, LLC 0.04% 16,750 0% 0.02% $44,220
LPL Financial LLC 0.03% 13,585 -7.5% 0% $35,864
BARCLAYS PLC 0.03% 13,198 0% 0% $34,843

Institutional Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 18,299 $56,178 -$1,535 $3.07 1
2025 Q3 9,209,933 $24,309,179 +$25,895 $2.64 47
2025 Q2 7,251,222 $16,313,647 -$1,273,421 $2.25 47
2025 Q1 7,771,787 $16,633,500 +$194,005 $2.14 52
2024 Q4 7,664,041 $18,546,600 +$1,145,502 $2.42 56
2024 Q3 6,959,875 $16,982,253 +$2,490,137 $2.44 55
2024 Q2 5,933,749 $15,249,519 +$1,726,909 $2.57 58
2024 Q1 5,261,652 $15,365,000 +$424,216 $2.92 52
2023 Q4 5,157,802 $11,912,739 +$6,473,921 $2.31 56
2023 Q3 2,294,684 $5,987,665 -$130,637 $2.61 54
2023 Q2 2,276,672 $8,150,136 -$6,036,465 $3.58 50
2023 Q1 4,261,808 $9,288,923 -$8,243,251 $2.18 58
2022 Q4 3,602,106 $43,330,122 +$3,068,606 $12.03 75
2022 Q3 3,913,540 $25,357,588 -$13,834,075 $6.48 64
2022 Q2 6,646,125 $30,238,806 -$18,679,490 $4.58 80
2022 Q1 8,309,238 $72,009,671 -$2,032,608 $8.65 94
2021 Q4 8,189,608 $116,892,193 +$37,342,205 $14.28 113
2021 Q3 5,412,384 $118,854,258 +$35,323,258 $21.98 91
2021 Q2 3,835,407 $51,315,524 +$35,103,676 $13.38 73
2021 Q1 1,236,112 $12,556,514 +$791,139 $10.16 44
2020 Q4 1,455,242 $6,168,000 -$1,611,514 $4.24 35
2020 Q3 1,999,732 $5,181,000 +$1,674,329 $2.61 33
2020 Q2 1,340,874 $4,694,000 +$2,530,472 $3.52 31
2020 Q1 612,062 $1,861,000 -$113,286 $3.04 26
2019 Q4 624,437 $3,215,000 -$405,068 $5.14 31
2019 Q3 752,619 $2,399,000 -$268,625 $3.19 25
2019 Q2 837,278 $3,004,000 -$844,481 $3.59 25
2019 Q1 1,072,115 $3,901,000 -$2,616,666 $3.64 24
2018 Q4 1,895,345 $5,688,000 +$413,925 $3.00 22
2018 Q3 1,710,835 $8,304,000 +$7,165,504 $4.86 25
2018 Q2 234,101 $1,740,000 +$40,272 $7.43 20
2018 Q1 256,135 $1,665,000 -$817,545 $6.51 19
2017 Q4 376,964 $3,397,549 +$788,109 $9.00 25
2017 Q3 274,779 $2,725,000 +$1,163,094 $9.92 22
2017 Q2 148,752 $1,157,000 +$276,206 $7.78 21
2017 Q1 147,982 $907,000 +$42,963 $6.10 19
2016 Q4 139,267 $850,000 -$375,230 $6.05 23
2016 Q3 180,537 $1,311,000 -$252,428 $7.26 20
2016 Q2 221,240 $1,844,000 +$546,004 $8.34 24
2016 Q1 100 $1,000 -$129,840 $6.65 2
2015 Q4 210,282 $1,781,840 +$387,453 $8.55 23
2015 Q3 155,594 $849,000 -$980,764 $5.47 16
2015 Q2 197 $2,000 +$1,000 $5.69 4
2015 Q1 100 $1,000 -$5,000 $8.19 2
2014 Q4 1,122 $6,000 -$155,148 $5.33 4
2014 Q3 1,375,959 $11,127,000 -$423,614 $8.07 18
2014 Q2 1,426,930 $13,726,430 +$928,262 $9.62 22
2014 Q1 1,311,737 $15,304,000 +$5,082,806 $11.78 21